ENCell Co Ltd
456070
Company Profile
Business description
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.
Contact
701 Yeongdong-daero
11th floor
Gangnam-gu
Seoul
KORT: +82 262058050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
112
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.90 | 9.20 | 0.10% |
| CAC 40 | 8,474.86 | 137.57 | 1.65% |
| DAX 40 | 25,580.88 | 540.60 | 2.16% |
| Dow JONES (US) | 52,565.64 | 260.40 | 0.50% |
| FTSE 100 | 10,652.87 | 174.53 | 1.67% |
| HKSE | 23,055.03 | 174.01 | 0.76% |
| NASDAQ | 25,696.37 | 343.66 | -1.32% |
| Nikkei 225 | 68,733.15 | 1,741.81 | -2.47% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,443.15 | 40.08 | -0.54% |
| S&P/ASX 200 | 8,724.50 | 13.90 | 0.16% |
| SSE Composite Index | 4,028.90 | 83.54 | -2.03% |